After Blocking Estrogen Signals in Brain, Experts Say They’ve ‘Never Seen Bone This Strong’
A handful of brain cells deep in the brain may play a surprising role in controlling women’s bone density, according to new research by UC San Francisco and UCLA scientists.
In a study published January 11, 2019 in Nature Communications, researchers showed that blocking a particular set of signals from these cells causes female (but not male) mice to build extraordinarily strong bones and maintain them into old age, raising hopes for new approaches to preventing or treating osteoporosis in older women.
“Our collaborators who study bone for a living said they’d never seen bone this strong,” said study senior author Holly Ingraham, PhD, who is professor and vice-chair of cellular and molecular pharmacology and Herzstein Distinguished Investigator in Molecular Physiology at UCSF. “Our current understanding of how the body controls bone growth can’t explain this, which suggests we may have uncovered a completely new pathway that could be used to improve bone strength in older women and others with fragile bones.”
More than 200 million people worldwide suffer from osteoporosis, a weakening of the bones to the point where falls or even minor stresses like bending over or coughing can trigger fractures. In healthy individuals, bone tissue is constantly being recycled – old bone tissue is broken down and replaced by new bone. As we age, this cycle tilts in favor of bone loss, causing our bones to become increasingly porous and fragile.
Women are at particularly high risk of osteoporosis after menopause (nearly one in three post-menopausal women in the US and Europe suffer from weakened bones) because of declining levels of the sex hormone estrogen, which normally promotes bone growth.
Estrogen plays many roles in the female body, particularly in the regulation of reproduction, but its function in the brain is still poorly understood. The Ingraham lab has long sought to understand how estrogen’s signaling in the brain impacts the female metabolism at different life stages, including how estrogen-sensitive neurons in a brain region called the hypothalamus balance energetic demands needed for survival or reproduction.
Their new study began when Stephanie Correa, PhD, then an Ingraham lab postdoctoral researcher and now an assistant professor at UCLA, found that genetically deleting the estrogen receptor protein in hypothalamic neurons caused mutant animals to gain a little weight, and also to become less active. Correa expected to find that the animals had put on extra fat or gained lean muscle, but these did not explain the difference. To find the source of the extra weight, she decided to use an extra-sensitive laboratory technique that could also reveal changes in bone density. To her surprise, she discovered that her heavy mice were truly just big-boned: the animals’ bone mass had increased by as much as 800 percent.
“I was immediately struck by the size of the effect. The two groups didn’t overlap at all, which I had never seen,” Correa said. “We knew right away it was a game changer and a new, exciting direction with potential applications for improving women’s health.”
The mutant animals’ extra-dense bones also proved to be super-strong. When collaborators such as UCSF’s Aaron Fields, PhD, an assistant professor in the Department of Orthopedic Surgery, tested the mechanical strength of these bones by crushing them, his equipment almost failed, Ingraham says.
After Correa moved to UCLA, Ingraham lab postdoctoral fellows Candice Herber, PhD, and William Krause, PhD, spearheaded a series of experiments that zeroed in on a specific population of just a few hundred estrogen-sensitive brain cells — located in a region of the hypothalamus called the arcuate nucleus — which appeared to be responsible for these dramatic increases in bone density. The authors hypothesized that estrogen must normally signal these neurons to shift energy away from bone growth, but that deleting the estrogen receptors had reversed that shift.
Notably, interfering with arcuate estrogen signaling in male mice appeared to have no effect. “Most neuroscientists limit studies to male mice, and few study estrogen, which may explain why this had never been seen before,” Ingraham said. “I’ve always been interested in how sex hormones make male and female brains different, and this is a really wonderful example of how dramatic those differences can be.”
Further experiments showed that Ingraham and Correa’s mutant animals maintained their enhanced bone density well into old age. Normal female mice begin to lose significant bone mass by 20 weeks of age, but mutant animals maintained elevated bone mass well into their second year of life, quite an old age by mouse standards.
Remarkably, Herber and Krause were even able to reverse existing bone degeneration in an experimental model of osteoporosis. In female mice that had already lost more than 70 percent of their bone density due to experimentally lowered blood estrogen, deletion of arcuate estrogen receptors caused bone density to rebound by 50 percent in a matter of weeks.
These results highlight the opposite roles played by estrogen in the blood, where it promotes bone stability, and in the hypothalamus, where it appears to restrain bone formation, Ingraham said. “We hypothesize that after puberty the estrogen system in the female brain actively shifts resources away from bone growth and towards things like reproduction, which could contribute to women’s higher risk of weakened bones as we age.”
The dramatic pattern of enhanced bone growth seen in the current study is unlike anything in the scientific literature, the researchers say, suggesting that Correa’s fortuitous discovery may have uncovered a totally novel biological pathway by which the brain regulates bone density. Ingraham and colleagues are now investigating exactly how this brain–bone communication happens, and whether drugs could be developed to boost bone strength in post-menopausal women without potentially dangerous effects of estrogen replacement therapy.
“This new pathway holds great promise because it allows the body to shift new bone formation into overdrive,” Correa said.
“I’m in the clouds about this result,” Ingraham added. “If our next experiments show that the brain releases a novel circulating factor that triggers enhanced bone growth, we might have a real chance of developing a drug that counteracts osteoporosis.”
The Latest on: Osteoporosis
via Google News
The Latest on: Osteoporosis
- Pharmalittle: Stronger warnings urged for Amgen’s osteoporosis drug; prices in drug ads can be jarring on April 17, 2019 at 5:47 am
Good morning. Elizabeth Cooney reporting from STAT’s worldwide headquarters in Boston today, with contributions from Ed Silverman before he takes a break from the news in favor of a cultural excursion ... […]
- New Amgen Osteoporosis Drug Priced at $1,825 a Month on April 16, 2019 at 3:40 pm
Amgen Inc.’s osteoporosis drug Evenity has been priced at $1,825 a month, or $21,900 a year, according to a media report published Monday. The U.S. list price covers a full 12-month course of ... […]
- Amgen's osteoporosis drug debuts with $22K annual price tag on April 16, 2019 at 11:43 am
Amgen's new osteoporosis drug Evenity will launch at a price of $1,825 per month or $21,900 annually, according to Reuters. The drug, approved by the FDA last week, is approved to treat osteoporosis ... […]
- New Treatment for Osteoporosis In Postmenopausal Women is Available on April 16, 2019 at 7:38 am
Amgen’s romosozumab-aqqg therapy (Evenity) for osteoporosis in postmenopausal women is now available for shipment to wholesalers in the United States. Approved by the FDA on April 9, 2019, the ... […]
- EVENITY™ (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture on April 15, 2019 at 10:30 pm
New Therapy to Cost One-Third Less Than Other Bone-Building Agents Over Full Course of Therapy THOUSAND OAKS, Calif., April 15, 2019 /PRNewswire/ -- Amgen (AMGN) today announced that EVENITY ... […]
- The facts about osteoporosis on April 15, 2019 at 3:20 pm
Osteoporosis is often seen as a problem for the elderly, and the National Osteoporosis Foundation notes that being over 50 is a major risk factor for osteoporosis. But that doesnÕt mean people ... […]
- How Lifestyle Choices Might be Putting You at Risk for Osteoporosis on April 15, 2019 at 3:02 pm
Many people are only vaguely familiar with osteoporosis, a disease which results in reduced bone density and quality. It’s often viewed as a normal part of the aging process. While age is a risk ... […]
- FDA Approves New Osteoporosis Treatment on April 11, 2019 at 5:31 am
TUESDAY, April 9, 2019 (HealthDay News) -- Many aging Americans face the risk of fractures due to osteoporosis. Now, they have a new means of fighting back, thanks to the U.S. Food and Drug ... […]
- New research could prevent jaw damage in patients being treated for cancer or osteoporosis on April 11, 2019 at 5:16 am
USC researchers and collaborators report a breakthrough to prevent damage to the jaw, a side effect suffered by some people undergoing treatment for cancer or osteoporosis. The newly published ... […]
- Second Time's The Charm For Amgen As FDA OKs Bone-Building Osteoporosis Drug on April 10, 2019 at 7:56 pm
Amgen, Inc. (NASDAQ: AMGN) — which was in the news late last week over a legal battle with Novartis AG (NYSE: NVS) over their migraine drug collaboration — now has a positive FDA decision to ... […]
via Bing News